Decoy Therapeutics Inc. filed a Certificate of Amendment on March 5, 2026, to effect a 1-for-12 reverse stock split of its common stock, effective 5:00 p.m. ET on March 6, 2026, reducing outstanding shares from approximately 6.38 million to 532,000 to comply with Nasdaq's continued listing requirements. Trading on a split-adjusted basis under ticker DCOY and new CUSIP 79400X602 begins March 9, 2026.
Key takeaways
Stockholders approved reverse split proposal (1-for-4 to 1-for-15) at February 24, 2026 Annual Meeting
Board approved 1-for-12 ratio on February 25, 2026
Certificate of Amendment filed March 5, 2026; effective March 6, 2026 at 5:00 p.m. ET
Outstanding shares reduced from ~6.38 million to ~532,000; authorized shares remain 100 million
Fractional shares rounded down with cash payment based on March 6 closing price
New CUSIP 79400X602; Equiniti Trust Company, LLC as exchange agent